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Abstract: Topoisomerase I is important for DNA replication and cell division, making it  
an attractive drug target for anticancer therapy. A series of indenoisoquinolines displaying 
potent Top1 inhibitory activity in human renal cell carcinoma cell line SN12C were selected 
to establish 3D-QSAR models using CoMFA and CoMSIA methods. Internal and external 
cross-validation techniques were investigated, as well as some measures taken, including 
region  focusing,  bootstrapping  and  the  “leave-group-out”  cross-validation  method.  The 
satisfactory  CoMFA  model  predicted  a  q
2  value  of  0.659  and  an  r
2  value  of  0.949, 
indicating that electrostatic and steric properties play a significant role in potency. The best 
CoMSIA  model,  based  on  a  combination  of  steric,  electrostatic  and  H-bond  acceptor 
descriptors, predicted  a  q
2  value of 0.523  and an  r
2 value of 0.902.  The models  were 
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graphically  interpreted  by  contour  plots  which  provided  insight  into  the  structural 
requirements for increasing the activity of a compound, providing a solid basis for future 
rational design of more active anticancer agents. 
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1. Introduction 
Kidney cancer is among the 10 most frequently occurring cancers in western communities. Globally, 
about 270,000 cases of kidney cancer are diagnosed yearly and 116,000 people die from the disease. 
Renal cell carcinoma (RCC) accounts for approximately 90% of all kidney cancers and its incidence  
is on the rise [1,2]. Localized RCC is curable with surgery but a third of patients are diagnosed with 
metastatic  RCC,  which  is  difficult  to  treat  and  is  generally  resistant  to  conventional  radiotherapy, 
chemotherapy  and  endocrine  therapy.  The  median  survival  for  patients  with  metastatic  RCC  is  
10–12  months  [3].  Despite  a  minority  of  patients  with  metastatic  disease  benefiting  from  cytokine 
immunotherapy,  a  need  still  exists  for  developing  more  effective  novel  anti-renal  cell  
carcinoma agents. 
Human topoisomerase type I (Top1) is a member of the topoisomerase family of enzymes that 
resolve the topological problems associated with DNA supercoiling during various essential cellular 
processes [4–6]. It forms a covalent link with the 3'-end of the cut DNA strand in the Top1-DNA 
cleavage complex at its catalytic tyrosine 723 residue, relieving torsional strain in DNA via reversible 
single-strand  nicks  [7,8].  Top1  is  important  for  the  successful  replication,  transcription  and 
recombination  of  DNA,  as  well  as  chromatin  remodeling,  making  it  an  attractive  drug  target  for 
anticancer therapy. Camptothecin, isolated and identified in 1966, was the first Top1 inhibitor [9]. 
Camptothecin derivatives irinotecan and topotecan approved by the Food and Drug Administration 
(FDA) validate Top1 as a therapeutic target for anticancer drug development [10]. In practice, these 
Top1  inhibitors  exert  a  promising  anticancer  effect  in  the  treatment  of  renal  cell  carcinoma.  For 
instance, clinically relevant concentrations of topotecan-induced apoptosis in RCC cell lines work more 
effectively  than  5-FU  [11].  In  addition,  combination  therapy  using  topotecan  and  survivin-specific 
siRNA could show a synergistic effect and offer an attractive approach for the treatment of advanced 
renal cancer [12,13].  In clinical practice, the use of a novel combination of irinotecan, cisplatin and 
mitomycin (IPM chemotherapy) produce symptomatic relief for a majority of patients with renal cancer 
following failure of cytokine immunotherapy [14]. However, these camptothecin derivatives are not 
ideal drug molecules, suffering from pharmacokinetic problems, inherent instability due to lactone ring 
opening  and  rapid  reversibility  of  the  cleavage  complexes  after  drug  removal  [15,16].  There  is  a 
present need for the development of noncamptothecin Top1 inhibitors as anticancer agents. Recently, a 
number of analogs of the indenoisoquinolines have been reported as novel anticancer agents [17–19]. 
The indenoisoquinoline Top1 inhibitors were examined for antiproliferative activity against different 
cancer  cell  lines.  The  results  indicate  that  these  novel  noncamptothecin  Top1  inhibitors  could  be 
potential agents for the treatment of a variety of cancers, including renal cancer. Among these derivatives, 
two indenoisoquinolines have been selected currently for clinical development by the NCI: NSC 725776 Int. J. Mol. Sci. 2012, 13  6011 
 
 
and NSC 724998 [20]. Both exert antiproliferative activity in submicromolar concentrations in cultured 
human cancer cell lines. 
The three-dimensional quantitative structure-activity relationship (3D-QSAR) techniques, including 
comparative  molecular  field  analysis  (CoMFA)  [21]  and  comparative  similarity  indices  analysis 
(CoMSIA) [22] are useful methods of ligand-based drug design used to correlate physicochemical 
descriptors from a set of related compounds to their known molecular activity or molecular property 
values  [23]. These computational  techniques incorporate 3D information for the ligands  and have  
been proved particularly helpful in the design of novel and more potent inhibitors. The application of 
QSAR  methodology  to  the  indenoisoquinoline  derivatives  hasn’t  been  reported.  The  satisfactory 
QSAR models on 48 indenoisoquinoline topoisomerase I inhibitors for their anti-renal cell carcinoma 
activities [18,19] provide a solid basis for future rational design of more active agents. 
2. Results and Discussion 
2.1. CoMFA Analysis 
The  compound  20,  one  of  the  most  active  molecules,  was  selected  as  the  template  and  the 
isoquinoline ring as the common structure for alignment (Figure 1). The CoMFA model provided a 
cross-validation q
2 value of 0.602 with 5 components, an r
2 value of 0.925 and an F-test value of 66.709 
(Table 1). Region focusing resulted in the better CoMFA model which showed a significant increase 
from 0.602 to 0.659 for the internal validity, 0.632 to 0.680 for group cross-validation, 0.790 to 0.826 for 
test set activity predictions, and from 0.925 to 0.949 for the non-validated r
2 (Table 1). Figure 2 shows 
CoMFA fields for molecule 20 before and after region focusing. The activity values predicted for the 
test set are in good agreement with the experimental values (Figure 3) and the rpred
2  value of 0.826 further 
confirms the reliability and accuracy of the model. The electrostatic and steric field contributions to the 
final model were 58.7% and 41.3%, respectively. 
Figure 1. Molecular alignment of indenoisoquinoline derivatives. 
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Table 1. Statistical results of CoMFA and best CoMSIA models. 
Statistical results 
CoMFA(before 
region focusing) 
CoMFA (after 
region focusing) 
CoMSIA (Model 5) 
PLS statistics 
*       
LOO cross q
2/SEP 
#  0.602/0.855  0.659/0.781  0.523/0.923 
Group cross q
2/SEP  0.632/0.822  0.680/0.757  0.524/0.922 
Non-validated r
2/SEE 
¤  0.925/0.367  0.949/0.334  0.902/0.436 
F  66.709  84.997  64.275 
r
2
bootstrap  0.918 ±  0.019  0.973 ±  0.020  0.906 ±  0.023 
Sbootstrap  0.387 ±  0.193  0.367 ±  0.135  0.373 ±  0.163 
Optimal components  5  5  5 
Field distribution%       
Steric  56.5  58.7  13.4 
Electrostatic  43.5  41.3  47.9 
H-bond acceptor      38.7 
r
2
pred  0.790  0.826  0.704 
* PLS = partial least squares, 
# LOO= leave-one-out, 
¤ SEE = standard errors of estimate. 
Figure 2. Region focusing. The CoMFA field calculations are shown for compound 20 
before (Upper) and after (Lower) region focusing. Steric fields (Left): Green fields indicate 
steric bulk favored, yellow fields indicate steric bulk disfavored. Electrostatic fields (Right): 
Blue  fields  indicate  electropositive  groups  favored,  red  fields  indicate  electronegative 
groups favored. 
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Figure 3. Graph of experimental versus predicted pGI50 of the training set and the test set 
using the CoMFA model. 
 
2.2. CoMSIA Analysis 
Twelve CoMSIA models were generated using combinations of 2, 3, 4, and all 5 descriptors as 
shown in Table 2. Model 5, based on steric, electrostatic and H-bond acceptor fields, was found to be 
the most accurate, yielding a q
2 value of 0.523 and an r
2 value of 0.902. The Group cross q
2 value of 
0.524, bootstrapped value of 0.906 ±  0.023 and test set r
2 value of 0.704 further approve the best 
CoMSIA model 5. The predicted values are closely consistent with the experimental data (Figure 4). 
The  steric  field  explains  13.4%  of  the  variance,  the  electrostatic  field  for  47.9%  and  the  H-bond 
acceptor field for 38.7% of the variance. 
Table 2. Results of CoMSIA models using combinations of the 5 field descriptors. 
Model  Descriptors 
LOO cross 
q
2/SEP 
Group cross 
q
2/SEP 
Bootstrap r
2 
Bootstrapped 
SEE 
Non-validated 
r
2/SEE 
1  S and E  0.474/0.970  0.490/0.955  0.865 ±  0.043  0.479 ±  0.262  0.857/0.507 
2  D and A  0.410/1.056  0.360/1.100  0.797 ±  0.066  0.599 ±  0.339  0.750/0.687 
3  S, E and H  0.520/0.929  0.523/0.923  0.788 ±  0.044  0.593 ±  0.198  0.767/0.637 
4  S, E and D  0.482/0.976  0.477/0.983  0.862 ±  0.034  0.496 ±  0.234  0.826/0.565 
5  S, E and A  0.523/0.923  0.524/0.922  0.906 ±  0.023  0.373 ±  0.163  0.902/0.436 
6  E, D and H  0.500/0.945  0.468/0.975  0.834 ±  0.055  0.528 ±  0.301  0.833/0.574 
7  E, A and H  0.511/0.923  0.500/0.933  0.757 ±  0.048  0.622 ±  0.296  0.765/0.639 
8  S, E, D and A  0.519/0.927  0.535/0.938  0.922 ±  0.019  0.379 ±  0.169  0.827/0.556 
9  S, E, D and H  0.503/0.942  0.560/0.886  0.834 ±  0.047  0.530 ±  0.274  0.816/0.574 
10  S, E, A and H  0.521/0.925  0.533/0.892  0.785 ±  0.062  0.596 ±  0.321  0.808/0.585 
11  S, D, A and H  0.453/0.996  0.484/0.987  0.870 ±  0.021  0.476 ±  0.174  0.833/0.562 
12  S, E, D, A and H  0.502/0.956  0.519/0.940  0.879 ±  0.051  0.437 ±  0.251  0.899/0.445 Int. J. Mol. Sci. 2012, 13  6014 
 
 
Figure 4. Graph of experimental versus predicted pGI50 of the training set and the test set 
using the best CoMSIA model 5. 
 
2.3. CoMFA Contour Maps 
The  results  of  3D-QSAR  models  are  presented  in  the  contour  coefficient  maps  as  shown  in  
Figure 5. Its steric interaction is denoted by green and yellow contours. Both a large green contour and 
a large yellow contour were located near the end of the side chain linking to the nitrogen atom of the 
isoquinoline ring of target compounds, indicating that steric fields did not play an important role in this 
region. This may be the reason why compounds 20 and 28 with almost the same chains showed the 
most and lowest activities, respectively. Similarly, compounds 1, 24, 28, 31 and 32 showed lower 
activity while compounds 3, 6, 17, 19 and 29 are more potent. Two large green and two small red 
contours around the 3-position of the isoquinoline ring suggest that bulky and electron-withdrawing 
substituents are required in this region to increase activity. This is possibly the reason why compound 
39 with the substitution of nitro group showed 24.5 times more potency than its corresponding mother 
compound 40, likewise 41 is 67.6 times greater than 42. A small red contour located near carbonyl 
group at position-11 of compound 20 indicates that electron-withdrawing groups are preferred in this 
region. This is why the compounds 43–47, whose carbonyl group at position-11 was replaced by other 
electron-donating  groups,  are  less  potent.  A  small  red  contour  near  the  methoxyl  substituted  at 
position-9 of compound 20 can be interpreted that groups with an electron-withdrawing factor are 
desired to increase the activity, and that is why compound 20 with the methoxyl group at position-9 is 
almost 7000 times more potent than its mother compound 24, also compounds 36 and 9 are far more 
potent than corresponding 35 and 33, respectively. A large yellow contour around position-1 signifies 
that the hydrogen atom must not be substituted. Int. J. Mol. Sci. 2012, 13  6015 
 
 
Figure 5. CoMFA contour maps of the highest active compound 20 and the lowest active 
compound 28. 
   
20  28 
2.4. CoMSIA Contour Maps  
The best CoMSIA model contour maps of the most active analog are shown in Figure 6. Its steric 
and electrostatic contour plots (Figure 6a,b) correlate well with the CoMFA contour maps described 
above.  Hydrogen-bond  acceptor  contour  maps  are  shown  in  Figure  6c.  Hydrogen  bond  
acceptor-favored regions are represented by magenta contours and unfavorable regions by cyan contours. 
One large magenta polyhedron is visible around the 3-position of the isoquinoline ring of compound 20, 
indicating that hydrogen-bond acceptor groups such as nitro, methoxyl group are very important for 
compound activity. Large cyan polyhedra around 2,4-positions of the isoquinoline ring and around the 
end  of  the  side  chain  adjacent  to  the  nitrogen  atom  of  the  isoquinoline  ring  can  be  interpreted  as 
disfavoring hydrogen-bond acceptor groups in these regions.  
Figure  6.  CoMSIA  fields.  The  CoMSIA  fields  from  model  5  are  shown  with  active 
compound 20; (a) Steric fields: green indicates steric bulk favored, yellow indicates bulk 
disfavored; (b) Electrostatic fields: blue indicates electropositive groups favored, red fields 
indicate  electronegative  groups  favored;  (c)  H-bond  acceptor  fields:  magenta  indicates 
acceptor favored, cyan disfavored. 
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Figure 6. Cont. 
 
(c) 
2.5. Design of New Inhibitors 
Based on the structure–activity relationship obtained by present 3D-QSAR models, a series of new 
inhibitors was designed and predicted (Table 3). With the most active molecule 20 in the training  
set used as the parent compound, some hydrogen-bond donors such as amino, hydroxyl and thiol were 
introduced at 3' or 4'-position of the heterocycle appended to the lactam side chain, and some bulky 
and  electron-withdrawing  groups,  such  as  nitro  and  cyan,  introduced  at  the  3-position.  Most  
(pGI50 > 8.5) greatly enhanced inhibitory activity in comparison to 20 (pGI50 = 8.145). In particular, 
compound 20-7 showed the strongest activity with its predicted pGI50 (9.029). Other compounds also 
exhibited good predicted activity as well as compound 20.  
Table 3. Results of CoMSIA models using combinations of the five field descriptors. 
N
R1
R3
R4
O
O
1
2
3
4 5
6
7
8
9 10
11
R2
 
No. 
Substituents  Predicted pGI50 
R1  R2  R3  R4  CoMFA  CoMSIA 
20  NO2  NH2  H  OCH3  8.145  8.195 
20-1  CN  NH2  H  OCH3  8.505  8.479 
20-2  CN  NH2  OCH3  OCH3  8.134  8.065 
20-3  CN  NH2  methylenedioxy  8.470  8.467 
20-4  NO2 
N
N
OH
 
OCH3  OCH3  8.599  8.557 
20-5  NO2 
N
N
NH2
 
methylenedioxy  8.657  8.701 
20-6  CN 
N
N
OH
 
OCH3  OCH3  8.878  8.770 
20-7  CN 
N
N
NH2
 
methylenedioxy  9.029  8.914 Int. J. Mol. Sci. 2012, 13  6017 
 
 
Table 3. Cont. 
No. 
Substituents  Predicted pGI50 
R1  R2  R3  R4  CoMFA  CoMSIA 
20-8  CN 
NH N
OH 
OCH3  OCH3  8.348  8.430 
20-9  NO2 
NH N
SH 
OCH3  OCH3  8.679  8.664 
20-10  CN  N N OH
 
OCH3  OCH3  8.889  8.791 
20-11  CN 
N
N
N
N
 
OCH3  OCH3  8.320  8.341 
20-12  CN  N
N
N
N
NH2
 
OCH3  OCH3  8.903  8.911 
20-13  CN  OH  methylenedioxy  8.303  8.295 
20-14  NO2  NH2  methylenedioxy  8.420  8.342 
20-15  CN  NH2
OH
  OCH3  OCH3  8.776  8.808 
3. Experimental Section  
3.1. Data Set 
Forty-eight  compounds  investigated  in  the  present  study  were  taken  from  the  published  works  
of  Morrell  A.  and  co-workers  [18,19].  The  structures  of  the  molecules  and  their  biological  data 
obtained  by  Morrell  A.  et  al.  are  given  in  Tables  4,5.  For  convenience,  we  have  converted  the 
cytotoxicity  GI50  values  of  topoisomerase  inhibitors  in  renal  carcinoma  cell  line  SN12C  to  their 
negative logarithm (pGI50) values, which have a span of 4.0 log units from 4.00 to 8.00, providing a 
broad and homogeneous data set for 3D-QSAR study (see Table 5) [24,25]. Seven compounds were 
randomly selected as the test set, based on the structural and active diversities with the remaining 41 
compounds as the training set.  
Table 4. The molecules of indenoisoquinoline derivatives. 
Compd.  N
R1
R2 R3
R4
R5
O
O
1
2
3
4 5
6
7
8
9 10
11
 
N
O
O
O
O
O
X
n
 
1–42  43–48 
R1  R2  R3  R4  R5 
  1 
*  OCH3  OCH3  CH3  methylenedioxy 
2  OCH3  OCH3  (CH2)3NH2  methylenedioxy Int. J. Mol. Sci. 2012, 13  6018 
 
 
Table 4. Cont. 
Compd.  R1  R2  R3  R4  R5 
3  OCH3  OCH3 
N
N
 
Methylenedioxy 
4  OCH3  OCH3 
N
N  
methylenedioxy 
5  OCH3  OCH3 
N
N
N
 
methylenedioxy 
6  OCH3  OCH3 
N
S
HN
 
methylenedioxy 
7  OCH3  OCH3 
NH N
  methylenedioxy 
8  OCH3  OCH3 
O N
  methylenedioxy 
9  OCH3  NO2 
N O
 
methylenedioxy 
10  OCH3  OCH3 
N
OH 
methylenedioxy 
  11 
*  OCH3  OCH3 
N N
  methylenedioxy 
12  OCH3  OCH3 
N NH2
 
methylenedioxy 
13  OCH3  OCH3 
N
NH
 
methylenedioxy 
  14 
*  OCH3  OCH3 
N N
OH
  methylenedioxy 
15  OCH3  OCH3 
N O
N
H  
methylenedioxy 
16  H  H  N
N
 
H  H 
  17 
*  OCH3  OCH3  N
N
 
H  H 
18  H  NO2  N
N
 
H  H 
19  H  NO2  (CH2)3Cl  H  OCH3 
20  H  NO2  (CH2)3NH2  H  OCH3 
21  H  H  (CH2)3Br  H  H 
22  H  H  (CH2)3NH2  H  H 
23  H  H  (CH2)3N(CH2)2  H  H 
24  H  NO2  (CH2)3N3  H  H 
25  H  NO2  (CH2)3NH2  H  H 
26  H  NO2  (CH2)3N(CH2)2  H  H 
  27 
*  H  NO2  (CH2)3Br  H  H 
28  H  H  (CH2)3N3  H  OCH3 
  29 
*  H  H  (CH2)3NH2  H  OCH3 
30  H  NO2  (CH2)3I  H  OCH3 
31  H  H 
N O
 
H  H 
32  H  H  (CH2)3N3  H  H Int. J. Mol. Sci. 2012, 13  6019 
 
 
Table 4. Cont. 
Compd.  R1  R2  R3  R4  R5 
33  H  NO2 
N O
 
H  H 
34  H  H 
N O
 
H  OCH3 
35  H  NO2  (CH2)3NH(CH2)3OH  H  H 
36  H  NO2  (CH2)3NH(CH2)3OH  H  OCH3 
37  H  H  (CH2)3NH(CH2)3OH  H  OCH3 
38  H  H  (CH2)3NH(CH2)3OH  H  H 
39  H  NO2  (CH2)3N(CH2)2  H  OCH3 
40  H  H  (CH2)3N(CH2)2  H  OCH3 
41  H  NO2 
N
N
 
H  OCH3 
42  H  H 
N
N
 
H  OCH3 
Compd.  n  X  Compd.  n  X 
43  3  Cl  46  5  Br 
44  3  Br  47  3  I 
45  4  Br  48 
*  2  NH2 
*Test set. 
Table5. Inhibitory activity and predicted values of indenoisoquinoline derivatives. 
Comp. no. 
Experiment 
(pGI50) 
CoMFA  CoMSIA 
Pred.  Res.  Pred.  Res. 
1 
*  4.168  4.003  0.165  4.335  −0.167 
2  6.509  6.571  −0.062  6.679  −0.170 
3  8.000  7.866  0.134  7.993  0.007 
4  6.500  6.324  0.176  6.691  −0.191 
5  7.071  7.206  −0.135  7.345  −0.274 
6  8.000  8.113  −0.113  7.776  0.224 
7  7.041  7.231  −0.190  7.135  −0.094 
8  6.090  6.004  0.086  5.890  0.200 
9  8.000  7.899  0.101  7.860  0.140 
10  6.900  6.798  0.102  7.079  −0.179 
11 
*  4.939  5.067  −0.128  5.163  −0.224 
12  6.590  6.497  0.093  6.889  −0.299 
13  6.839  7.000  −0.161  7.132  −0.293 
14 
*  4.000  3.761  0.239  4.476  −0.476 
15  5.830  5.812  0.018  6.337  −0.507 
16  5.780  5.770  0.010  5.910  −0.130 
17 
*  8.000  8.198  −0.198  8.403  −0.403 
18  7.824  7.793  0.031  7.850  −0.026 
19  8.000  7.885  0.115  8.063  −0.063 
20  8.000  8.145  −0.145  8.195  −0.195 
21  5.155  4.996  0.159  4.666  0.489 
22  6.796  6.689  0.107  6.535  0.261 Int. J. Mol. Sci. 2012, 13  6020 
 
 
Table 5. Cont. 
Comp. no. 
Experiment 
(pGI50) 
CoMFA  CoMSIA 
Pred.  Res.  Pred.  Res. 
23  6.041  6.003  0.038  5.990  0.051 
24  4.140  4.095  0.045  4.003  0.137 
25  6.991  7.023  −0.032  6.840  0.151 
26  5.380  5.187  0.193  5.580  −0.200 
27 
*  4.000  3.695  0.305  4.443  −0.443 
28  4.000  4.010  −0.010  4.147  −0.147 
29 
*  8.000  7.797  0.203  7.694  0.306 
30  6.510  6.550  −0.040  6.443  0.067 
31  4.670  4.535  0.135  4.871  −0.201 
32  4.600  4.569  0.031  4.575  0.025 
33  6.510  6.511  −0.001  6.505  0.005 
34  4.070  4.034  0.036  4.104  −0.034 
35  6.640  6.650  −0.010  6.497  0.143 
36  7.921  7.905  0.016  8.133  −0.212 
37  6.801  6.932  −0.131  7.004  −0.203 
38  6.570  6.494  0.076  6.610  −0.040 
39  8.000  8.049  −0.049  7.949  0.051 
40  6.611  6.376  0.235  6.911  −0.300 
41  8.000  8.001  −0.001  8.021  −0.021 
42  6.170  6.003  0.167  6.250  −0.080 
43  4.000  4.138  −0.138  4.517  −0.517 
44  4.000  4.158  −0.158  4.231  −0.231 
45  4.000  3.946  0.054  3.879  0.121 
46  5.244  5.201  0.043  5.290  −0.046 
47  5.056  4.875  0.181  4.756  0.300 
48 
*  6.237  6.040  0.197  6.660  −0.423 
* Test set. 
3.2. Molecular Alignment 
Compared  to  probe  atom  type,  lattice  shifting  step  size  and  overall  orientation  of  the  aligned 
compounds, a good alignment is the most important element for CoMFA and CoMSIA analysis [26], 
and the alignment rules will directly determine the quality and the predictive ability of the model. The 
alignment  was  often  performed  in  accordance  with  some  rules,  such  as  substructure  overlap, 
pharmacophore overlap and docking [27] as soon as the active conformation was obtained by energy 
minimization using Powell method and Tripos standard force field [28]. Here, the isoquinoline ring 
with structural rigidity was selected as the common substructure to overlap and to align all of the 
molecules and the most active compound 20 was used as the alignment template. Alignment of all 
compounds  was  shown  in  Figure  1.  It  can  be  seen  that  all  the  compounds  studied  have  similar  
active conformations. Int. J. Mol. Sci. 2012, 13  6021 
 
 
3.3. Partial Least Squares (PLS) Analysis 
To  linearly  correlate  the  3D-QSAR  fields  to  biological  activity  values,  PLS  analysis  [29]  was 
performed.  It  was  firstly  carried  out  by  the  leave-one-out  (LOO)  and  leave-group-out  (10  groups)  
cross-validation  methods  to  determine  cross-validated  r
2  (q
2)  values  and  the  optimal  number  of 
components on the basis of the lowest standard error of prediction (SEP) and avoiding over-fitting  
the models. A higher component was accepted and used only when the q
2 differences between two 
components  were  larger  than  5%.  Non-cross-validation  was  then  performed  to  establish  the  final  
3D-QSAR  model  with  the  values  of  conventional  correlation  coefficient  (r
2),  standard  errors  of 
estimate (SEE), and F ratio between the variances of calculated and observed activities given.  
The q
2 has been a good indicator of the accuracy of actual predictions. In general, q
2 values can be 
separated into three categories: q
2 > 0.6 means a fairly good model, q
2 = 0.4–0.6 means a questionable 
model, and q
2 < 0.4 a poor model [30]. q
2 is calculated as follows: 
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where, Yobs = experimental activity, Ypre = predicted activity, Ymean = mean activity. 
To further assess the robustness of the derived models, bootstrapping analysis (10 runs) was also 
utilized  to  calculate  confidence  intervals  for  the  r
2  and  SEE  [29,31].  The  equation  for  SEE  is  
given below. 
1
PRESS
SEE
nc

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Where n means number of compounds, c means number of components, and PRESS (predicted sum of 
squares) means  (Yobs-Ypre)
2
. 
3.4. Predictive Correlation Coefficient 
q
2 is a useful but not sufficient criterion for model validation, so an external test set (rpred
2 ) [32] was 
claimed for the estimation of predictive ability. Equation of predictive values rpred
2  is as follows: 
2 1 ( / ) pred r PRESS SD   
Therein, SD means the sum of squared differences between the measured activities of the test set 
and the average measured activity of the training set. 
3.5. CoMFA Studies 
Three-dimensional  grid  spacing  was  set at  2 Å in  the  x,  y,  and  z  directions  and  automatically 
generated to be a 3D cubic lattice that extended at least 4 Å beyond the van der Waals volume of all 
aligned molecules in all directions. Lennard-Jones potential and Coulomb potential were employed to 
calculate steric and electrostatic energies of each molecule using the Tripos force field [28], and the 
sp
3-hybrized carbon atom with a +1 charge taken as the probe atom to determine the magnitude of the 
field values. The regression analysis was carried out using the partial least squares (PLS) method [29]. Int. J. Mol. Sci. 2012, 13  6022 
 
 
All energies that exceeded the cutoff value of 30 kcal/mol were replaced with 30 kcal/mol for the 
reduction of domination by large steric and electrostatic energies [33]. The column filtering was set to 
2.0 kcal/mol and those lattice points whose energy variation was below this threshold were automatically 
omitted, consequently the signal-to-noise ratio was improved. The final model was developed with the 
optimum  number  of  components  to  yield  a  non-cross-validated  r
2  value.  Despite  being  unable  to 
describe all of the binding forces, CoMFA is still a useful tool for QSAR analysis at the 3D level. 
One method of 3D-QSAR optimization is known as region focusing [34], which may enhance or 
attenuate the contribution of the lattice points in a further analysis of a given CoMFA or CoMSIA region. 
Generally, region focusing can maximize the q
2 value by rotating the extracted principal components, 
and give a new model with increased predictive power (q
2), enhanced resolution, tighter grid spacing, 
and greater stability at a higher number of components.  
3.6. CoMSIA Studies 
CoMSIA is an extension of CoMFA on the same assumption that changes in binding affinities  
of ligands are related to changes in molecular properties represented by fields. Besides steric and 
electrostatic fields, three other different fields (hydrophobic, hydrogen bond donor, and hydrogen bond 
acceptor) are calculated in CoMSIA [35]. Moreover, a Gaussian function was introduced to determine 
the distance between the probe atom and the molecule atoms, and similarity indices inside and outside 
different molecular surfaces can be calculated at all grid points in CoMSIA. The equation used to 
calculate the similarity indices is as follows: 
2
, ( ) ,
iq r q
F K j probe k ik
i
A W W e
  
 
Where, A is the similarity index at grid point q, summed over all atoms i of the molecule j under 
investigation. Wprobe, k is the probe atom with radius 1 Å, charge +1, hydrophobicity +1, hydrogen bond 
donating +1 and hydrogen bond accepting +1. Wik is the actual value of the physicochemical property k 
of atom i. riq is the mutual distance between the probe atom at grid point q and atom i of the test 
molecule. α is the attenuation factor whose optimal value is normally between 0.2 and 0.4, with a 
default value of 0.3 [36,37]. 
4. Conclusions  
In conclusion, our present studies have established predictive CoMFA and CoMSIA models that are 
quite reliable to efficiently guide further modification in the molecules for obtaining better drugs. Both 
of  them  provided  good  statistical  results  in  terms  of  q
2  and  r
2  values,  suggesting  the  significant 
correlations of molecular structures with its biological activities. Compared with CoMSIA, CoMFA 
provided a slightly better statistical model. The final CoMFA model has high internal validity (q
2 above 
0.5)  and  high  predictive  ability  (test  set  r
2  above  0.7).  The  3D-QSAR  results  also  revealed  some 
important sites, where steric, electrostatic and hydrogen-bond acceptor modifications should significantly 
affect  the  bioactivities  of  these  compounds.  Thus,  the  results  of  the  quantitative  structure  activity 
relationships (QSAR) studies give insight into how to design new inhibitors, and it can be expected that Int. J. Mol. Sci. 2012, 13  6023 
 
 
these novel derivatives could be more active anticancer agents in the treatment of renal cell carcinoma 
as well. 
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